EHS
EHS

The Future of Fatty Liver: From Education to Anticipated Approvals



The increasing prevalence of nonalcoholic fatty liver disease and its progressive form, nonalcoholic steatohepatitis, presents a significant need for therapeutic options. While no specific therapy or medication has yet received approval for treating NAFLD and NASH, several therapeutics are under clinical evaluation, some of which have already reached phase 3 testing. These therapeutic regimens, once approved, along with improved diagnostics and screening, and increased education and awareness of these diseases, will lead the way to better patient outcomes.
Most experts agree that the future of

Source link

EHS
Back to top button